Research press release


Nature Medicine

Understanding response to clopidogrel



D Taubertたちは、パラオキソナーゼ-1(PON1)がクロピドグレル活性化に不可欠であることを明らかにした。そして、ステント血栓形成予防のためにクロピドグレル投与を受けている移植を受けて冠動脈疾患患者群で、PON1の変異と臨床像の関連を調べた。PON1のQQ192という遺伝子型をもつ患者は、RR192という遺伝子型の患者に比べてステント血栓症を起こすリスクが高かった。また、血漿中のPON1活性、活性なクロピドグレル濃度ともにRR192患者よりも低く、血小板の阻害の程度も低かった。

A genetic basis for the variable clinical response to the anti-blood clot drug clopidogrel is presented this week in Nature Medicine. This finding may be exploited to assess in advance the clinical efficacy of this popular drug in each patient.

Clopidogrel is one of the most widely prescribed blood clotting medicines worldwide, but its efficacy is hampered by patient differences in the metabolic processing necessary for the drug to become active. This variability has been attributed to genetic factors, but the specific genes underlying clopidogrel activation are disputed.

Dirk Taubert and his colleagues report that paraoxonase-1 (PON1) is the crucial enzyme for clopidogrel activation. The authors tested the clinical relevance of genetic variants of PON1 in a group of patients with coronary artery disease who underwent stent implantation and received clopidogrel to prevent thrombosis. Patients with the PON1 QQ192 genotype showed a higher risk of stent thrombosis than patients with the RR192 genotype. The QQ192 patients also had lower PON1 plasma activity, lower plasma concentrations of active drug and less platelet inhibition than the RR192 group.


doi: 10.1038/nm.2281


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。